6 results about "SORBITAN TRIOLEATE" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The application belongs to the technical field of biological medicine, and particularly relates to an adjuvant influenza vaccine and a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS buffer solution; the adjuvant is prepared by using mixed oil and an auxiliary agent, the mixed oil comprises squalene, medium-chain triglyceride and alpha-tocopherol; and the auxiliary agent comprises sorbitan trioleate Span-85, Tween 80 and vitamin E succinate polyethylene glycol ester. The adjuvant influenza vaccine prepared by the application has good immunization effect, and can especially improve the overall effect of a tetravalent adjuvant influenza vaccine on four viruses.

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze (E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The application discloses a squalene-based water-in-oil-in-water vaccine adjuvant and a vaccine composition and application thereof. The adjuvant comprises squalene, tocopherol, lipophilic surfactant and a hydrophilic surfactant combination composed of polyglyceryl dioleate, decaglyceryl monolaurate and polyoxyethylene sorbitan trioleate in a specific mass ratio. The specific combination is the key to forming a stable and uniform squalene multiple emulsion. The vaccine composition prepared by mixing and emulsifying the adjuvant with an antigen shows excellent physical stability, enhanced immune response and good safety in animal experiments, and is especially suitable for preventing bovine nodular dermatosis and preparation of positive serum thereof. The application solves the technical problem that squalene is difficult to stabilize in a complex emulsion system, and provides a replacement scheme superior to a traditional mineral oil adjuvant.

The invention relates to the technical field of vaccine preparations, and discloses an oil-in-water adjuvant containing squalene as well as a preparation method and application of the oil-in-water adjuvant. Polysorbate 80; sorbitan trioleate; a temperature sensitive nonionic block copolymer; an amino acid CMT modulator; a polyol CMT modifier; citric acid; sodium citrate; and the balance of water for injection. The preparation method comprises the following steps: preparing an oil phase; the preparation method comprises the following steps: dissolving a temperature-sensitive nonionic block copolymer, a CMT regulator, citric acid and sodium citrate in low-temperature water for injection, and carrying out heating pretreatment to obtain a water phase; shearing and emulsifying the water phase and the oil phase at a specific temperature; and finally, carrying out speed-controlled cooling and filtering on the hot emulsion. Through the composite formula and the specific process, the long-term storage stability of the adjuvant is remarkably improved, the immunocompetence of the vaccine is guaranteed, the process reproducibility is good, and the production cost is reduced.

The application relates to the technical field of vaccine preparation, and discloses an oil-in-water squalene-containing adjuvant as well as a preparation method and application thereof. The adjuvant comprises the following components: squalene, polysorbate 80, sorbitan trioleate, a temperature-sensitive nonionic block copolymer, an amino acid CMT regulator, a polyhydric alcohol CMT regulator, citric acid, sodium citrate, and the rest is injection water. The preparation method comprises the following steps: preparing an oil phase; dissolving the temperature-sensitive nonionic block copolymer, the CMT regulator, the citric acid and the sodium citrate in low-temperature injection water, then pre-treating by temperature rising to obtain an aqueous phase; shearing and emulsifying the aqueous phase and the oil phase at a specific temperature; and finally, controlling the cooling speed of the hot emulsion and filtering. Through the composite formula and the specific process, the long-term storage stability of the adjuvant is remarkably improved, the immunocompetence of the vaccine is guaranteed, the process reproducibility is good, and the production cost is reduced.